Analysts think LRMR stock price could increase by 480%
Dec 25, 2024, 12:26 PM
-3.97%
What does LRMR do
Larimar Therapeutics, based in Bala Cynwyd, Pennsylvania, focuses on developing novel therapeutics for mitochondrial disorders and Friedreich's ataxia using its cell penetrating peptide technology. Its lead candidate, nomlabofusp, aims to deliver essential protein frataxin to mitochondria for treating this rare disease.
12 analysts think LRMR stock price will increase by 480.16%. The current median analyst target is $21.93 compared to a current stock price of $3.78. The lowest analysts target is $14.14 and the highest analyst target is $37.80.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.